48 related articles for article (PubMed ID: 34364187)
1. Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries.
Wenzel M; Collà Ruvolo C; Nocera L; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Graefen M; Becker A; Mandel P; Chun FKH; Karakiewicz PI
Cancer Epidemiol; 2021 Oct; 74():101994. PubMed ID: 34364187
[TBL] [Abstract][Full Text] [Related]
2. Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course?
Porcaro AB; Bianchi A; Panunzio A; Gallina S; Serafin E; Tafuri A; Trabacchin N; Orlando R; Ornaghi PI; Mazzucato G; Vidiri S; D'Aietti D; Montanaro F; Brusa D; Patuzzo GM; Artoni F; Baielli A; Migliorini F; De Marco V; Veccia A; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
Int Urol Nephrol; 2024 Mar; ():. PubMed ID: 38553619
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Registries: Current Status and Future Directions.
Gandaglia G; Bray F; Cooperberg MR; Karnes RJ; Leveridge MJ; Moretti K; Murphy DG; Penson DF; Miller DC
Eur Urol; 2016 Jun; 69(6):998-1012. PubMed ID: 26056070
[TBL] [Abstract][Full Text] [Related]
4. Chronic Glucocorticoid Use and Risk for Advanced Prostate Cancer at Presentation: A SEER-Medicare Cohort Study.
Singh Z; Holt SK; Gore JL; Nyame YA; Wright JL; Schade GR
Clin Genitourin Cancer; 2024 Apr; 22(2):68-73.e2. PubMed ID: 37806926
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer.
Sandhu S; Moore CM; Chiong E; Beltran H; Bristow RG; Williams SG
Lancet; 2021 Sep; 398(10305):1075-1090. PubMed ID: 34370973
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and outcome of radical prostatectomy following inductive neoadjuvant therapy in patients with suspicion of rectal infiltration.
Hoeh B; Preisser F; Wenzel M; Humke C; Wittler C; Köllermann J; Bodelle B; Bernatz S; Steuber T; Tilki D; Graefen M; Karakiewicz PI; Becker A; Kluth LA; Chun FKH; Mandel P
Urol Oncol; 2022 Feb; 40(2):59.e7-59.e12. PubMed ID: 34456124
[TBL] [Abstract][Full Text] [Related]
7. Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response.
Grubmüller B; Jahrreiss V; Brönimann S; Quhal F; Mori K; Heidenreich A; Briganti A; Tilki D; Shariat SF
Curr Oncol; 2021 Jul; 28(4):2881-2892. PubMed ID: 34436018
[TBL] [Abstract][Full Text] [Related]
8. Association between preoperative prostate-specific antigen levels and mortality in high- and intermediate-grade prostate cancer patients who received radical prostatectomy: Findings from the SEER database.
Ikuemonisan J; Lediju O; Togun A; Adejoro O
Prostate Int; 2021 Jun; 9(2):72-77. PubMed ID: 34386448
[TBL] [Abstract][Full Text] [Related]
9. Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study.
Liu AQ; Remmers S; Lau SY; Yip SY; Leung CH; Mak CW; Yee CH; Teoh JY; Hou SM; Roobol M; Ng CF; Chiu PK
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):684-689. PubMed ID: 34453109
[TBL] [Abstract][Full Text] [Related]
10. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
12. Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance: The ERASE Randomized Clinical Trial.
Kang DW; Fairey AS; Boulé NG; Field CJ; Wharton SA; Courneya KS
JAMA Oncol; 2021 Oct; 7(10):1487-1495. PubMed ID: 34410322
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
Van Poppel H; Roobol MJ; Chapple CR; Catto JWF; N'Dow J; Sønksen J; Stenzl A; Wirth M
Eur Urol; 2021 Dec; 80(6):703-711. PubMed ID: 34407909
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes among localized prostate cancer survivors: prospective predictors for return-to-work three years after cancer rehabilitation.
Ullrich A; Rath HM; Otto U; Kerschgens C; Raida M; Hagen-Aukamp C; Bergelt C
Support Care Cancer; 2022 Jan; 30(1):843-854. PubMed ID: 34392427
[TBL] [Abstract][Full Text] [Related]
15. Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis.
Wenzel M; Deuker M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Becker A; Roos FC; Chun FKH; Karakiewicz PI
Eur J Cancer; 2021 Sep; 155():245-255. PubMed ID: 34392067
[TBL] [Abstract][Full Text] [Related]
16. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract][Full Text] [Related]
17. Observation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications.
Kwon YS; Wang W; Srivastava A; Jang TL; Singer EA; Parikh RR; Kim WJ; Kim IY
Prostate Int; 2021 Jun; 9(2):82-89. PubMed ID: 34386450
[TBL] [Abstract][Full Text] [Related]
18. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.
Freedland SJ; De Giorgi U; Gleave M; Rosbrook B; Shen Q; Sugg J; Haas GP; Shore ND
BMJ Open; 2021 Aug; 11(8):e046588. PubMed ID: 34385241
[TBL] [Abstract][Full Text] [Related]
19. When staging becomes screening: public education is the key.
Varma M; Narahari K
BMJ; 2021 Aug; 374():n1853. PubMed ID: 34380628
[No Abstract] [Full Text] [Related]
20. High-intensity interval training or resistance training versus usual care in men with prostate cancer on active surveillance: a 3-arm feasibility randomized controlled trial.
Papadopoulos E; Gillen J; Moore D; Au D; Kurgan N; Klentrou P; Finelli A; Alibhai SMH; Santa Mina D
Appl Physiol Nutr Metab; 2021 Dec; 46(12):1535-1544. PubMed ID: 34380000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
